





















































































**ISBT 128 Standard  
Standard Terminology for Blood, Cellular Therapy, and Tissue Product  
Descriptions (previously called Product Coding: Bounded Lists and Definitions)**

**Version Control Sheet**

	<b>Section</b>	<b>Change</b>	<b>Rationale</b>
<b>Version 3.45 December 2010</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.44 November 2010</b>			
1	2.2.1	Added "Washed Thawed" and "Washed Thawed Apheresis" modifiers	Requested by Poland
2	4.1.1	Added a "TIBIA SHAFT" tissue class	Requested by Canada
<b>Version 3.43 October 2010</b>			
1	2.3.1	Added PAS-F	Requested by vendor
<b>Version 3.42 September 3, 2010</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.41 September 1, 2010</b>			
1	4.1.1	Added the following class names: TENDON, TIBIALIS, ANTERIOR; TENDON, TIBIALIS, POSTERIOR; TIBIA; HUMERUS; HUMERUS DISTAL; HUMERUS PROXIMAL; TENDON PLANTARIS; ANKLE; RIB; FIBULA; HAMSTRING; CORTICOCANCELLOUS BONE, CRUSHED; CORTICOCANCELLOUS BONE, GROUND; SAPHENOUS VEIN	Requested by Canada
2	4.3.2.1	Added an attribute group for	Better managed as an



		Anatomical Position	attribute
3	4.3.2.2.5	Added Anatomical Position attribute group variables	Better managed as an attribute
<b>Version 3.40 August 2010</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.39 July 2010</b>			
1	2.3.1.1	Added descriptions in the table of volumes	Clarity
<b>Version 3.38 June 2010</b>			
1	3.1.1	Added NC, ADIPOSE CELLS	Requested by CTCLAG
2	3.1.1	Added NC, MENSTRUAL BLOOD	Requested by CTCLAG
<b>Version 3.37 May 2010</b>			
1	2.1.1	Removed LYMPHOCYTES and MONOCYTES from the Class table	Retired these terms for the labeling of blood products. These products will be classified as cellular therapy products.
2	4.1	Added a "TISSUE" class	Requested by NATTAG
3	6.1.1	Added LYMPHOCYTES and MONOCYTES to the retired blood Class table	Retired these terms for the labeling of blood products. These products will be classified as cellular therapy products.
<b>Version 3.36 April 2010</b>			
1	4.3.2.1	Rearranged the group names so they are listed in the same order as they appear in the Attribute table of the Product Code Database.	Consistency
2	5.2.1	Added a "Thawed" modifier	Requested by Sweden
3	5.3.1.1	Added a "refg" storage temperature	Requested by Sweden
<b>Version 3.35 March 2010</b>			
1	2.3.1	Added a table of the renamed platelet additive solutions with standard <i>ISBT 128</i> terminology and defined them based on their key ingredients.	PASs have non-standard terminology. Two solutions with basically the same ingredients may be called by different names by different companies. Therefore, <i>ISBT 128</i> defines platelet additive solutions in terms of their key



			ingredients.
2	2.3.1.1	Added extra examples to the unbounded list of volumes and temperatures.	To provide a better global representation.
3	2.3.2.2.12	Added new attribute of 0.4-0.5 to the Hematocrit attribute group.	Requested by Hong Kong
4	Appendix A	Relocated the table of platelet additive solutions.	Incorporated this information into section 2.3.1
<b>Version 3.34 February 2010</b>			
1	3.3.2.2.3	Added NS DMSO cryoprotectant attribute	Requested by Canada
2	3.3.2.2.3	Revised definitions to describe DMSO concentration of the actual product, not just the frozen product	Clarity
<b>Version 3.33 January 2010</b>			
1	3.2.1	Added Pooled, Single Donor Thawed Washed	Requested by the US
<b>Version 3.32 December 2009</b>			
1	2.3.1	Added a note in reference to Appendix A	To provide explanation to new PAS naming convention
2	2.3.1.1	Defined PASIIIMgK in terms of its ingredients.	To provide greater clarity
3	2.3.1.1	Added PAS-E.	Requested by Belgium.
4	2.3.1.1	Changed wording of definitions from, "The Plasma was frozen within..." to "The Plasma was placed in the freezer within..."	To give greater flexibility for different practices worldwide.
5	Appendix A	Added Appendix A to the end of the document.	To provide explanation to new PAS naming convention
<b>Version 3.31 October 2009</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.30 September 2009</b>			
1	Throughout document	Alphabetized lists of classes, modifiers, and attributes	Ease in search
2	2.3.2.1	Removed the Platelet Count Attribute Group	Attribute group retired
3	6.1.2.3	Added Platelet Count Attribute Group	Attribute group retired
4	2.3.2.2.1	Revised definition for "Not for tx or mnf" attribute	Clarification





<b>Version 3.29 August 2009</b>			
1	3.2.1	Added new modifier combination and definition for Cryopreserved Non-Mobilized	Requested by Sweden. Inadvertent omission in the February 2009 version control.
2	3.2.1	Added new modifier combination and definition for Thawed Washed Non-Mobilized	Requested by Sweden. Inadvertent omission in the February 2009 version control.
<b>Version 3.28 July 2009</b>			
1	2.3.1.1	Removed reference to Composol for PASIIIMgK	Inappropriate use of commercial name
<b>Version 3.27 June 2009</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.26 May 2009</b>			
1	2.3.1.1	Added new anticoagulant of CPD-50>SAGM.	Requested by Canada
<b>Version 3.25 April 2009</b>			
1	3.3.2.2.3	Added new attribute of 7.5% DMSO.	Requested by the US. This attribute was added to the database as part of version 3.18 in September 2008 but was inadvertently omitted from the Standard Terminology document.
<b>Version 3.24 March 2009</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.23 February 2009</b>			
1	3.3.2.2.3	Removed "DMSO reduced" from the Cryoprotectant attribute group	The Thawed Washed modifier includes DMSO reduction. The two terms describe the same process.
2	6.2.3.3.6	Added a retired table for the Cryoprotectant attribute group with the "DMSO reduced" attribute	Retired cellular therapy attribute
<b>Version 3.22 January 2009</b>			
1	3.1.1	Revised the definition for TC-	This name should not be used



		INV	for a product that is part of a blinded comparison study.
2	3.1.1	Added new Class and definition for TC-BLINDED STUDY	Requested by CTCLAG
<b>Version 3.21 December 2008</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.20 November 2008</b>			
1	3.1.1	Changed the Class name from TC-Tumor Derived to TC, Tumor Derived	TC, Tumor may be a collected product. A hyphen always indicates a final product, but a comma may either be a collection product or a final product.
2	3.1.1	Added new Class and definition for TC-TIL	Requested by CTCLAG
3	3.3.2.2.1	Revised the definitions for the Intended Use Group attribute variables	Clarity; products collected as "not for administration" may be further processed into non-transfusable products.
<b>Version 3.19 October 2008</b>			
1	3.3.2.2.2	Added Monocytes enriched	Requested by Austria
<b>Version 3.18 September 2008</b>			
1	Pg. 2	Added copyright message	
2	2.3.1	Omitted the text explanation for NS, None, and XX as part of the core conditions definitions	Duplication with the core conditions table
3	2.3.1.1	Revised definition of "XX" in the core conditions volume table	Clarity
4	2.3.1.1	Revised the definitions for "rt" and "20 – 24 C" in the core conditions temperature table	Clarity
5	2.3.1.1	Revised the definition for "None" in the core conditions anticoagulant table	Clarity
6	6.1.2.1	Retired the use of None/NS/<=-18C, None/NS/rt, and DMSO/NS/<-80C core conditions	Discontinued the use of "NS" to specify blood collection volume. The revised definition of XX will allow it to be used in place of "NS".



<b>Version 3.17 August 2008</b>			
1		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.16 July 2008</b>			
1	2.3.1.1	Added CPD>AS3	At the request of the US
2	2.3.1.1	Added CPD>SAGM	At the request of Canada. Previous codes for SAGM do not include the anticoagulant, which is required in Canada
<b>Version 3.15 June 2008</b>			
1	3.1.2	Added standardized abbreviations	These terms are commonly abbreviated in documents and standardization is desirable.
2	6.2.3.1	Deleted alb, HES, NaCitrates, Plasma and SSPP from Core Conditions retired codes	These terms only appeared in conjunction with other terms. The combinations are already on the list.
3	6.2.3.3.2	Indicated 6% HES + 5% DMSO and 10% DMSO have been moved to the Cryoprotectant group.	Clarity
4	6.2.3.3.4	Added From Buffy Coat, Density Enriched, and CD56 enriched	Inadvertently omitted.
<b>Version 3.14 May 2008</b>			
Title	Title	Title of document has been changed to Standard Terminology for Blood, Cellular Therapy, and Tissue Product Descriptions	To better describe the purpose of the document.
1	1	Changed title of chapter	To better describe the introductory nature of chapter
2	1	Reworded chapter	To better describe how product descriptions are created within the ISBT 128 Standard
3		Deleted information indicating that some terms found in the database do not appear in this in this document	These terms now appear in the chapter on retired codes
4	2.3.2.2.5	Added Complement inactivated	At the request of Sweden
5	2.3.2.2.7	Added Frozen <=26h	At the request of Austria



6	3.1	Explained the categories of Cellular Therapy classes	Improve clarity
7	6.2.1	Deleted TC, Whole Blood	Error correction. This code is not retired.
8	6.2.3.3.2	Deleted 6%HES + 5% DMSO and 10% DMSO	Error correction. These codes are not retired.
<b>Version 3.13 March 2008</b>			
1	2.1.1	Added POOLED FRESH FROZEN PLASMA as a product class	Per the request of Spain
2	3	Indicated information about "retired codes" could be found in Chapter 6 as well as in the Transition document	Retired code definitions are now included in this document
3	5	Added a chapter on retired codes.	A mechanism to retire codes (maintain them in the database for backwards compatibility but recommend against their use for new products) was established.
<b>Version 3.12 February 2008</b>			
1	1	Reworded	To add clarity and to include Derivatives
2	4.1.1	Added TENDON, PATELLA, WHOLE, SHAPED	Per request of the UK
3	5	Added Chapter 5, Derivatives	Per request of Finland
<b>Version 3.11, January 2008</b>			
1	2.3.2.2.11	Added Riboflavin-treated	Per request of US
<b>Version 3.10, December 2007</b>			
1	2.3.1.1	Added PASIIIMgK	Per request of Spain
<b>Version 3.9, November 2007</b>			
1	2.3.2.2.9	Added Quar:>=90d/retested	Per request of Spain
<b>Version 3.8, October 2007</b>			
1		No changes were made to this document. The numbering was updated to correspond with current Product Code Description database.	
<b>Version 3.7, August 2007</b>			
1	1	Indicated requests for new product codes should be submitted via an on-line request form. Indicated where instructions for product codes requests may be found, Explained why some codes	Clarified the process



		found in the database are not present in the Product Coding Bounded Lists and Definitions document.	
2	2.3.2.2.1	Reworded definition for “For mnf: non-injectable restr use	Clarity and consistency
3	2.3.2.2.1	Added attribute for “For mnf: injectable restr use	Request of the US
4	4.1.2	Redefined the following Class terms: <ul style="list-style-type: none"> <li>• Pericardial Patch</li> <li>• Aortic Arch</li> <li>• Aortic Patch</li> <li>• Cardiovascular Non-Valved Conduit</li> <li>• Meniscus</li> <li>• Meniscus, Left</li> <li>• Meniscus, Right</li> <li>• Tendon, Patella, Left</li> <li>• Tendon, Patella, Right</li> <li>• Tibia, Proximal, Left</li> <li>• Tibia, Proximal, Right</li> </ul>	More accurate definitions
5	4.1.2	Redefined the Modifier Cleaned Frozen	More accurate definition
6	4.1.2	Changed Class names (from →to) and re-alphabetized: <ul style="list-style-type: none"> <li>• Acellular Pericardial Patch → Pericardial Patch</li> <li>• Cancellous Bone Knee Slice → Cancellous Femoral Knee Slice</li> <li>• Cardiovascular Non-Valved Conduits → Aortic Non-Valved Conduit</li> <li>• Cortical Bone Ring → Cortical Femoral Bone Ring</li> <li>• Cortical Strip → Cortical Femoral Bone Strip</li> <li>• Cortico-Cancellous Bone Ring → Cortico-Cancellous Femoral Bone Ring</li> <li>• Cortico-Cancellous Bone Strip → Cortico-Cancellous Femoral Bone Strip</li> <li>• Whole Meniscus → Menisci</li> </ul>	More accurate descriptions <i>Note: Names which appear as label text may be nationally defined. Therefore, changes in names to the database do not have to affect the name printed on the label. However, consideration should be given to using the more accurate terms for products labeled in the future.</i>



		<ul style="list-style-type: none"> <li>• Meniscus, Whole, Left → Menisci, Left</li> <li>• Meniscus, Whole, Right → Menisci, Right</li> <li>• Tendon, Semitendinosus → Tendon, Semitendinosus</li> </ul>	
7	4.1.2	Deleted Pericarium Pool	While term will be retained in the database for backward compatibility, it should not be selected for new products
8	4.1.2	Added Tendon, Semitendinosus, Left and Tendon Semitendinosus, Right	Inadvertently omitted from this document.
9	4.1.2	Added class: Cancellous Tibial Knee Slice	Per request of Poland and the UK
10	4.2.1	Added modifier: Cleaned Frozen Acellular	Per request of Poland and the UK
11	4.3.2.2.2	Added definition for Paracetic Acid	Completeness
<b>Version 3.6, July 2007</b>			
1	3.2.2.4	Deleted "Not Specified" as the default value. Made "No third party component added" the default value.	The default value should be the most common condition. "Not specified" is not the most common condition.
2	3.2.2.5	Deleted "Not Specified" as the default value. Made "No additives other than as part of the anticoagulant solution at the time of collection" the default value.	The default value should be the most common condition. "Not specified" is not the most common condition.
3	3.2.2.6	Deleted "Not specified" as the default value. Made "Not genetically modified" the default value.	The default value should be the most common condition. "Not specified" is not the most common condition.
<b>Version 3.5, June 2007</b>			
1	3.1	Redefined class terms: <ul style="list-style-type: none"> <li>• HPC, APHERESIS</li> <li>• HPC, CORD</li> <li>• HPC, MARROW</li> <li>• HPC, WHOLE BLOOD</li> <li>• TC, APHERESIS</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.



		<ul style="list-style-type: none"> <li>• CONCURRENT PLASMA, APHERESIS</li> <li>• TC, APHERESIS</li> </ul>	
2	3.1	Changed HPC, CORD to HPC, CORD BLOOD	More precise term.
3	3.1	<p>Retired Class terms (these codes should not be assigned to NEW products but are maintained for backward compatibility):</p> <ul style="list-style-type: none"> <li>• T CELLS</li> <li>• T CELLS, APHERESIS</li> <li>• LYMPHOCYTES, APHERESIS</li> <li>• POOLED, HPC, APHERESIS</li> <li>• MNC, APHERESIS</li> <li>• TC-T</li> <li>• TC-CTL, APHERESIS</li> <li>• TC, WHOLE BLOOD</li> <li>• TC-T, WHOLE BLOOD</li> <li>• TC-CTL, WHOLE BLOOD</li> <li>• TC-DC, MARROW</li> <li>• TC-DC, CORD</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
4	3.1	<p>Added Class terms:</p> <ul style="list-style-type: none"> <li>• TC, MARROW</li> <li>• TC, WHOLE BLOOD</li> <li>• TC, CORD BLOOD</li> <li>• TC-T CELLS</li> <li>• TC-CTL</li> <li>• TC-T REG CELLS</li> <li>• TC-DC</li> <li>• TC-NK CELLS</li> <li>• TC-TUMOR DERIVED</li> <li>• TC-MSC</li> <li>• TC-APC</li> <li>• TC-INV</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG).
5	3.2.1	<p>Redefined Modifier terms:</p> <ul style="list-style-type: none"> <li>• Cryopreserved</li> <li>• Thawed</li> <li>• Heparinized</li> <li>• Washed</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
6	3.2.1	Retired modifiers term: Frozen	Was redundant with Cryopreserved
7	3.2.1	Added Modifier terms:	Per the Cellular Therapy



		<ul style="list-style-type: none"> <li>• Mobilized</li> <li>• Non-mobilized</li> <li>• Pooled, Single Donor</li> <li>• Thawed Washed</li> </ul>	Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
8	3.3.1.1	<p>Retired anticoagulants (these codes should not be assigned to NEW products but are maintained for backward compatibility):</p> <ul style="list-style-type: none"> <li>• ACD-A</li> <li>• ACD-A+10% DMSO</li> <li>• ACD-A+Heparin</li> <li>• ACD-A + Heparin+6% HES</li> <li>• ACD-A + Heparin+6% HES + 10% DMSO</li> <li>• Alb</li> <li>• CPD</li> <li>• CPD+Heparin</li> <li>• CPDA-1</li> <li>• CPDA-1 + DMSO</li> <li>• CPDA-1+10% DMSO+30% SSPP+10% plasma</li> <li>• CPDA-1+10% DMSO+0.8% HES+1% dextran</li> <li>• DMSO</li> <li>• HES</li> <li>• HES-DMSO</li> <li>• NaCitrate</li> <li>• PBS</li> <li>• PBS + alb + 4% NaCitrate</li> <li>• Plasma</li> <li>• SSPP</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
9	3.3.1.1	<p>Redefined anticoagulant terms:</p> <ul style="list-style-type: none"> <li>• Heparin</li> <li>• None</li> <li>• Not specified</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
10	3.3.1.1	<p>Added anticoagulants:</p> <ul style="list-style-type: none"> <li>• Citrate</li> <li>• Citrate and Heparin</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
11	3.3.1.1	Redefined storage	Per the Cellular Therapy





		temperatures: <ul style="list-style-type: none"> <li>• rt</li> </ul>	Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
12	3.3.1.1	Added Storage Temperature: <ul style="list-style-type: none"> <li>• <math>\leq -150^{\circ}\text{C}</math></li> <li>• <math>\text{N}_2</math></li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
13	3.3.2.1	Retired Attribute groups (these codes should not be assigned to NEW products but are maintained for backward compatibility): <ul style="list-style-type: none"> <li>• System Integrity</li> <li>• Preparation: Additional Information</li> <li>• Final Product: Additional Information</li> <li>• Further Processing</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
14	3.3.2.1	Redefined Attribute group term: <ul style="list-style-type: none"> <li>• Manipulation</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
15	3.3.2.1	Added Attribute groups: <ul style="list-style-type: none"> <li>• Preparation: Cryoprotectant</li> <li>• Preparation: Blood component from third party donor</li> <li>• Preparation: Additional additives</li> <li>• Genetically modified</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
16	3.3.3.1 (Version 3.5: 3.3.2.2.1)	Reworded variables in Intended Use group: <ul style="list-style-type: none"> <li>• Changed “For Transfusion” to “For Administration”</li> <li>• Changed “Not for tx” to “Not for administration or further processing”</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
17	3.3.3.1 (Version 3.5: 3.3.2.2.1)	Added a variable to the Intended Use group: <ul style="list-style-type: none"> <li>• For further processing</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product</i>



			<i>Coding Transition Document</i> for rationale.
18	3.3.3.2	Retired variables from the System Integrity Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility):	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
19	3.3.3.3	Retired variables from the Preparation: Additional Information Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility):	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
20	3.3.3.4	Retired variables from the Final Product: Additional Information Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility):	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
21	3.3.3.5 (Version 3.5: 3.3.2.2.2)	Retired variable terms from Manipulation Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility): <ul style="list-style-type: none"> <li>• Minimal</li> <li>• Extensive</li> <li>• CD8-depleted</li> <li>• CD34-removed</li> <li>• AC133-selected</li> <li>• From buffy coat</li> <li>• T-Cells depleted</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
22	3.3.3.5 (Version 3.5: 3.3.2.2.2)	Redefined variable terms from Manipulation Attribute group: <ul style="list-style-type: none"> <li>• CD34-enriched</li> <li>• PUV-treated</li> <li>• Buffy coat enriched</li> <li>• RBC-reduced</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
23	3.3.3.5 (Version 3.5: 3.3.2.2.2)	Added variables to the Manipulation Attribute group: <ul style="list-style-type: none"> <li>• Diluted</li> <li>• Plasma reduced</li> <li>• Mononuclear cells enriched</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.



		<ul style="list-style-type: none"> <li>• T-cell reduced</li> <li>• B-cell reduced</li> <li>• T/B-cell reduced</li> <li>• CD8 reduced</li> <li>• CD34 enriched</li> <li>• CD133 enriched Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.</li> <li>• Tumor cells reduced</li> <li>• Cultured</li> </ul>	
24	3.3.3.6	<p>Retired variable terms from Further Processing Attribute group (these codes should not be assigned to NEW products but are maintained for backward compatibility)</p> <ul style="list-style-type: none"> <li>• Default: No further processing</li> <li>• Volume DMSO reduced</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
25	Version 3.5: 3.3.2.2.3	<p>Added variable terms to Cryoprotectant group:</p> <ul style="list-style-type: none"> <li>• 6% HES + 5% DMSO</li> <li>• 10% DMSO</li> <li>• 5% DMSO</li> <li>• DMSO reduced</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
26	Version 3.5: 3.3.2.2.4	<p>Added variable terms to Preparation: Blood component from third party donor group</p> <ul style="list-style-type: none"> <li>• Default: Not Specified</li> <li>• 3<sup>rd</sup> Party Component: No</li> <li>• 3<sup>rd</sup> party Component: Yes</li> </ul>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
27	Version 3.5: 3.3.2.2.5	<p>Added variable terms to Preparation: Other Additives group</p> <p>Default: Not specified</p> <p>Other additives: No</p> <p>Other additives: yes</p>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i> for rationale.
28	Version 3.5: 3.3.2.2.6	<p>Added variable terms to Genetically Modified Group</p> <p>Default: Genetic modification not specified</p> <p>Genetically modified: No</p>	Per the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). See <i>Cellular Therapy Product Coding Transition Document</i>



		Genetically modified: Yes	for rationale.
<b>Version 3.4, May 2007</b>			
1	2.3.3.10	Added 10 donor pool to Dosage: Additional Information Group	Per request of the US
2	4.1	Added Calcar Femorale	Per request of Denmark
<b>Version 3.3, April 2007</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 3.2, March 2007</b>			
1	2.3.1.1	Added NaCitrate—HES—ACD-A	Per request of the US
<b>Version 3.1.x, February 2007</b>			
1	2.3.1	Updated reference in note to current edition of Mollison's Blood Transfusion in Clinical Medicine	Update
2	2.3.1.1	Added MAP as an additive; corrected spelling of "hydroxyl"	Per request of China; typographical error
3	2.3.3.14	Added definition of default for monitoring	Inadvertent omission
4	2.3.3.4	Added ResLeu:<2.5log6	Per request of China
5	2.3.3.6	Added 25 mL and 50 mL	Per request of China
6	2.3.3.7	corrected spelling of "hydroxyl"	Typographical error
7	3.3.1.1	Added definition for "XX"	Inadvertent omission
8	3.3.3.1	Corrected spelling of citrate	Typographical error
<b>Version 3.0, January 2007</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 2.18, December 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database.	
<b>Version 2.17, November 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code	



		Description database.	
<b>Version 2.16, September 2006</b>			
	4.1	Revised or added definitions for Costal Cartilage, Osteochondral, bone and tendon.	
<b>Version 2.15, August 2006</b>			
	2.3.3.5	Added Plasma Reduced/Plasma added	Per request of the US
	2.3.3.6	Change ml to mL	Typographical error
<b>Version 2.14, July 2006</b>			
1	4.1	Added AORTIC PATCH	Per request of the UK
2	4.1	Added PULMONARY PATCH	Per request of the UK
3	4.1	Alphabetized classes	Ease of use
<b>Version 2.13, June 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database	
<b>Version 2.12, April 2006</b>			
		No changes made to this document. Numbering updated to correspond with current Product Code Description database	